Literature DB >> 26332786

Decreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer.

Takayuki Goto1, Naoki Terada1, Takahiro Inoue1, Takashi Kobayashi1, Kenji Nakayama1, Yoshiyuki Okada1, Takeshi Yoshikawa1, Yu Miyazaki1, Masayuki Uegaki1, Noriaki Utsunomiya1, Yuki Makino1, Shinji Sumiyoshi2, Toshinari Yamasaki1, Tomomi Kamba1, Osamu Ogawa1.   

Abstract

BACKGROUND: Human prostate cancers are highly heterogeneous, indicating a need for various novel biomarkers to predict their prognosis. Lipid metabolism affects numerous cellular processes, including cell growth, proliferation, differentiation, and motility. Direct profiling of lipids in tissue using high-resolution matrix-assisted laser desorption/ionization imaging mass spectrometry (HR-MALDI-IMS) may provide molecular details that supplement tissue morphology.
METHODS: Prostate tissue samples were obtained from 31 patients, with localized prostate cancer who underwent radical prostatectomy. The samples were assessed by HR-MALDI-IMS in positive mode, with the molecules identified by tandem mass spectrometry (MS/MS). The effect of identified molecules on prostate specific antigen recurrence free survival after radical prostatectomy was determined by Cox regression analysis and by the Kaplan-Meier method.
RESULTS: Thirteen molecules were found to be highly expressed in prostate tissue, with five being significantly lower in cancer tissue than in benign epithelium. MS/MS showed that these molecules were [lysophosphatidylcholine (LPC)(16:0/OH)+H](+), [LPC(16:0/OH)+Na](+), [LPC(16:0/OH)+K](+), [LPC(16:0/OH)+matrix+H](+), and [sphingomyelin (SM)(d18:1/16:0)+H](+). Reduced expression of LPC(16:0/OH) in cancer tissue was an independent predictor of biochemical recurrence after radical prostatectomy.
CONCLUSIONS: HR-MALDI-IMS showed that the expression of LPC(16:0/OH) and SM(d18:1/16:0) was lower in prostate cancer than in benign prostate epithelium. These differences in expression of phospholipids may predict prostate cancer aggressiveness, and provide new insights into lipid metabolism in prostate cancer.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  biomarker; imaging mass spectrometry; lipid; lysophosphatidylcholine; prostate cancer

Mesh:

Substances:

Year:  2015        PMID: 26332786     DOI: 10.1002/pros.23088

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  27 in total

Review 1.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Authors:  Lisa M Butler; Ylenia Perone; Jonas Dehairs; Leslie E Lupien; Vincent de Laat; Ali Talebi; Massimo Loda; William B Kinlaw; Johannes V Swinnen
Journal:  Adv Drug Deliv Rev       Date:  2020-07-23       Impact factor: 15.470

2.  Molecular Characterization of Prostate Cancer with Associated Gleason Score Using Mass Spectrometry Imaging.

Authors:  Elizabeth C Randall; Giorgia Zadra; Paolo Chetta; Begona G C Lopez; Sudeepa Syamala; Sankha S Basu; Jeffrey N Agar; Massimo Loda; Clare M Tempany; Fiona M Fennessy; Nathalie Y R Agar
Journal:  Mol Cancer Res       Date:  2019-02-11       Impact factor: 5.852

3.  Removal of optimal cutting temperature (O.C.T.) compound from embedded tissue for MALDI imaging of lipids.

Authors:  Jacob X M Truong; Xander Spotbeen; Jake White; Johannes V Swinnen; Lisa M Butler; Marten F Snel; Paul J Trim
Journal:  Anal Bioanal Chem       Date:  2021-02-09       Impact factor: 4.142

4.  MALDI Mass Spectrometry Imaging Highlights Specific Metabolome and Lipidome Profiles in Salivary Gland Tumor Tissues.

Authors:  Eduardo Sommella; Emanuela Salviati; Vicky Caponigro; Manuela Grimaldi; Simona Musella; Alessia Bertamino; Luigi Cacace; Remo Palladino; Giuseppe Di Mauro; Federico Marini; Anna Maria D'Ursi; Pietro Campiglia
Journal:  Metabolites       Date:  2022-06-08

5.  Shotgun Lipidomics for Differential Diagnosis of HPV-Associated Cervix Transformation.

Authors:  Natalia L Starodubtseva; Vitaliy V Chagovets; Maria E Nekrasova; Niso M Nazarova; Alisa O Tokareva; Olga V Bourmenskaya; Djamilja I Attoeva; Eugenii N Kukaev; Dmitriy Y Trofimov; Vladimir E Frankevich; Gennady T Sukhikh
Journal:  Metabolites       Date:  2022-05-31

Review 6.  Advances in Lipidomics for Cancer Biomarkers Discovery.

Authors:  Francesca Perrotti; Consuelo Rosa; Ilaria Cicalini; Paolo Sacchetta; Piero Del Boccio; Domenico Genovesi; Damiana Pieragostino
Journal:  Int J Mol Sci       Date:  2016-11-28       Impact factor: 5.923

Review 7.  Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications.

Authors:  Naoki Terada; Shusuke Akamatsu; Takashi Kobayashi; Takahiro Inoue; Osamu Ogawa; Emmanuel S Antonarakis
Journal:  Ther Adv Med Oncol       Date:  2017-07-05       Impact factor: 8.168

Review 8.  Prostate cancer diagnosis and characterization with mass spectrometry imaging.

Authors:  Annika Kurreck; Lindsey A Vandergrift; Taylor L Fuss; Piet Habbel; Nathalie Y R Agar; Leo L Cheng
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-12-05       Impact factor: 5.554

Review 9.  An Updated Review of Pro- and Anti-Inflammatory Properties of Plasma Lysophosphatidylcholines in the Vascular System.

Authors:  Eva Knuplez; Gunther Marsche
Journal:  Int J Mol Sci       Date:  2020-06-24       Impact factor: 5.923

10.  Reduced levels of N'-methyl-2-pyridone-5-carboxamide and lysophosphatidylcholine 16:0 in the serum of patients with intrahepatic cholangiocarcinoma, and the correlation with recurrence-free survival.

Authors:  Kyung-Hee Kim; Jungnam Joo; Boram Park; Sang-Jae Park; Woo Jin Lee; Sung-Sik Han; Tae Hyun Kim; Eun Kyung Hong; Sang Myung Woo; Byong Chul Yoo
Journal:  Oncotarget       Date:  2017-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.